Global Epigenetics Diagnostics Market Size Study, by Product, by Application, by Technology, by End User and Regional Forecasts 2022-2032

Description

The Global Epigenetics Diagnostics Market was valued at USD 14.76 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 15.10% from 2024 to 2032. Epigenetics diagnostics involves the study of chemical modifications to DNA and proteins that regulate gene expression without altering the underlying genetic code. By analysing these epigenetic markers, such as DNA methylation and histone modifications, diagnostic tests can provide insights into an individual's susceptibility to certain diseases, predict disease progression, and inform personalized treatment strategies.

Epigenetic alterations play a crucial role in the development and progression of chronic diseases, such as cancer, cardiovascular disorders, and neurological conditions, offering valuable insights into their molecular mechanisms. As healthcare systems worldwide grapple with the burden of chronic illnesses, there is a growing need for early detection and personalized treatment strategies, which epigenetics diagnostics can fulfill. Epigenetic biomarkers associated with disease risk and progression empower clinicians to implement proactive interventions, thereby enhancing patient outcomes and optimizing healthcare efficiency. Consequently, the increasing incidence of chronic diseases fuels the demand for epigenetics diagnostics, driving market growth and innovation in the field.

Innovations such as next-generation sequencing (NGS), high-throughput DNA methylation arrays, and single-cell epigenomics platforms have revolutionized the accuracy, speed, and cost-effectiveness of epigenetic analysis. These technologies enable comprehensive profiling of epigenetic modifications across the genome, offering deeper insights into disease mechanisms and biomarker discovery. Moreover, the integration of bioinformatics tools facilitates data analysis and interpretation, enhancing the clinical utility of epigenetics diagnostics. These technological advancements expand the scope of epigenetic research and drive the development of novel diagnostic assays and personalized treatment strategies, driving market growth. Also, healthcare providers and patients increasingly recognize the importance of individual genetic and epigenetic variations in disease susceptibility, progression, and treatment response, leading to heightened demand for diagnostic tools capable of offering tailored insights. Epigenetic diagnostic tests have the ability to assess epigenetic modifications, which influence gene expression and hold immense promise in enabling personalized treatment strategies across various medical specialties. This awareness fosters greater adoption of epigenetics diagnostic tests among clinicians and patients, driving market growth as healthcare systems increasingly prioritize precision medicine approaches to improve patient outcomes and optimize healthcare delivery.

North America dominated the market with a revenue share of 38.18% in 2023. The large share is mainly attributed to government support and the presence of major companies. High awareness among people, advanced medical infrastructure, and high R&D expenditure are some of the other factors that support the market growth in the region. Moreover, the high prevalence of chronic diseases and increasing investment by market participants for the development of epigenetics will boost regional growth further. The market in the Asia Pacific region is projected to grow at the fastest CAGR of 17.2% from 2024 to 2032. The Asia Pacific market is expected to rise owing to increasing investment in research & development activities by the government and growing incidences of cancer.

Major market players included in this report are:

Bio-Techne. (U.S.)
Promega Corporation (U.S.)
GeneTex, Inc. (U.S.)
PacBio (U.S.)
Illumina, Inc. (U.S.)
Merck KGaA (Germany)
QIAGEN (Germany)
F. Hoffmann-La Roche Ltd (Switzerland)
Eisai Co., Ltd. (Japan)
Novartis AG (Switzerland)
Diagenode s.a. (U.S.)
Active Motif, Inc. (U.S.)
Zymo Research Corporation. (U.S.)
Thermo Fisher Scientific (U.S.)
Syndax (U.S.)

The detailed segments and sub-segments of the market are explained below:

By Product:

Enzymes
Instruments and Consumables
Kits
Reagents

By Application:

Oncology
Metabolic Diseases
Developmental Biology
Immunology
Cardiovascular Diseases
Others

By Technology:

DNA Methylation
Histone Methylation
Others

By End User:

Academic and Research Institutes
Pharmaceutical Companies and Biotechnology Companies
Contract Research Organizations (CROs)

By Region:

North America
- U.S.
- Canada
Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
Latin America
- Brazil
- Mexico
- RoLA
Middle East & Africa
- Saudi Arabia
- South Africa
- RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Epigenetics Diagnostics Market Executive Summary

1.1. Global Epigenetics Diagnostics Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Product
- 1.3.2. By Application
- 1.3.3. By Technology
- 1.3.4. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Epigenetics Diagnostics Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Epigenetics Diagnostics Market Dynamics

3.1. Market Drivers
- 3.1.1. Escalating Prevalence of Chronic Diseases
- 3.1.2. Rising Advancements in Technology
3.2. Market Challenges
- 3.2.1. High Complexity of Interpreting Epigenetic Data
3.3. Market Opportunities
- 3.3.1. Growing Awareness of Personalized Medicine
- 3.3.2. High Strategic Collaborations

Chapter 4. Global Epigenetics Diagnostics Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Epigenetics Diagnostics Market Size & Forecasts by Product 2022-2032

5.1. Segment Dashboard
5.2. Global Epigenetics Diagnostics Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Enzymes
- 5.2.2. Instruments and Consumables
- 5.2.3. Kits
- 5.2.4. Reagents

Chapter 6. Global Epigenetics Diagnostics Market Size & Forecasts by Application 2022-2032

6.1. Segment Dashboard
6.2. Global Epigenetics Diagnostics Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Oncology
- 6.2.2. Metabolic Diseases
- 6.2.3. Developmental Biology
- 6.2.4. Immunology
- 6.2.5. Cardiovascular Diseases
- 6.2.6. Others

Chapter 7. Global Epigenetics Diagnostics Market Size & Forecasts by Technology 2022-2032

7.1. Segment Dashboard
7.2. Global Epigenetics Diagnostics Market: Technology Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. DNA Methylation
- 7.2.2. Histone Methylation
- 7.2.3. Others

Chapter 8. Global Epigenetics Diagnostics Market Size & Forecasts by End User 2022-2032

8.1. Segment Dashboard
8.2. Global Epigenetics Diagnostics Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 8.2.1. Academic and Research Institutes
- 8.2.2. Pharmaceutical Companies and Biotechnology Companies
- 8.2.3. Contract Research Organizations (CROs)

Chapter 9. Global Epigenetics Diagnostics Market Size & Forecasts by Region 2022-2032

9.1. North America Epigenetics Diagnostics Market
- 9.1.1. U.S. Epigenetics Diagnostics Market
  - 9.1.1.1. Product breakdown size & forecasts, 2022-2032
  - 9.1.1.2. Application breakdown size & forecasts, 2022-2032
  - 9.1.1.3. Technology breakdown size & forecasts, 2022-2032
  - 9.1.1.4. End User breakdown size & forecasts, 2022-2032
- 9.1.2. Canada Epigenetics Diagnostics Market
9.2. Europe Epigenetics Diagnostics Market
- 9.2.1. U.K. Epigenetics Diagnostics Market
- 9.2.2. Germany Epigenetics Diagnostics Market
- 9.2.3. France Epigenetics Diagnostics Market
- 9.2.4. Spain Epigenetics Diagnostics Market
- 9.2.5. Italy Epigenetics Diagnostics Market
- 9.2.6. Rest of Europe Epigenetics Diagnostics Market
9.3. Asia-Pacific Epigenetics Diagnostics Market
- 9.3.1. China Epigenetics Diagnostics Market
- 9.3.2. India Epigenetics Diagnostics Market
- 9.3.3. Japan Epigenetics Diagnostics Market
- 9.3.4. Australia Epigenetics Diagnostics Market
- 9.3.5. South Korea Epigenetics Diagnostics Market
- 9.3.6. Rest of Asia Pacific Epigenetics Diagnostics Market
9.4. Latin America Epigenetics Diagnostics Market
- 9.4.1. Brazil Epigenetics Diagnostics Market
- 9.4.2. Mexico Epigenetics Diagnostics Market
- 9.4.3. Rest of Latin America Epigenetics Diagnostics Market
9.5. Middle East & Africa Epigenetics Diagnostics Market
- 9.5.1. Saudi Arabia Epigenetics Diagnostics Market
- 9.5.2. South Africa Epigenetics Diagnostics Market
- 9.5.3. Rest of Middle East & Africa Epigenetics Diagnostics Market

Chapter 10. Competitive Intelligence

10.1. Key Company SWOT Analysis
10.2. Top Market Strategies
10.3. Company Profiles
- 10.3.1. Bio-Techne
  - 10.3.1.1. Key Information
  - 10.3.1.2. Overview
  - 10.3.1.3. Financial (Subject to Data Availability)
  - 10.3.1.4. Product Summary
  - 10.3.1.5. Market Strategies
- 10.3.2. Promega Corporation
- 10.3.3. GeneTex, Inc.
- 10.3.4. PacBio
- 10.3.5. Illumina, Inc.
- 10.3.6. Merck KGaA
- 10.3.7. QIAGEN
- 10.3.8. F. Hoffmann-La Roche Ltd
- 10.3.9. Eisai Co., Ltd.
- 10.3.10. Novartis AG
- 10.3.11. Diagenode s.a.
- 10.3.12. Active Motif, Inc.
- 10.3.13. Zymo Research Corporation
- 10.3.14. Thermo Fisher Scientific
- 10.3.15. Syndax

Chapter 11. Research Process

11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
11.2. Research Attributes